In Vitro and In Vivo Neuroprotective Effects of Stellettin B Through Anti-Apoptosis and the Nrf2/HO-1 Pathway

Pharmaceutical agents for halting the progression of Parkinson’s disease (PD) are lacking. The current available medications only relieve clinical symptoms and may cause severe side effects. Therefore, there is an urgent need for novel drug candidates for PD. In this study, we demonstrated...

Full description

Bibliographic Details
Main Authors: Chien-Wei Feng, Nan-Fu Chen, Zhi-Hong Wen, Wen-Ya Yang, Hsiao-Mei Kuo, Ping-Jyun Sung, Jui-Hsin Su, Shu-Yu Cheng, Wu-Fu Chen
Format: Article
Language:English
Published: MDPI AG 2019-05-01
Series:Marine Drugs
Subjects:
Online Access:https://www.mdpi.com/1660-3397/17/6/315
Description
Summary:Pharmaceutical agents for halting the progression of Parkinson’s disease (PD) are lacking. The current available medications only relieve clinical symptoms and may cause severe side effects. Therefore, there is an urgent need for novel drug candidates for PD. In this study, we demonstrated the neuroprotective activity of stellettin B (SB), a compound isolated from marine sponges. We showed that SB could significantly protect SH-SY5Y cells against 6-OHDA-induced cellular damage by inhibiting cell apoptosis and oxidative stress through PI3K/Akt, MAPK, caspase cascade modulation and Nrf2/HO-1 cascade modulation, respectively. In addition, an in vivo study showed that SB reversed 6-OHDA-induced a locomotor deficit in a zebrafish model of PD. The potential for developing SB as a candidate drug for PD treatment is discussed.
ISSN:1660-3397